Sumagen’s World First Killed Whole HIV Vaccine Set For Phase II
After a positive outcome from a US Phase I study, South Korea's Sumagen is stepping closer to the launch of the world's first killed-whole HIV vaccine with potential to both prevent and treat AIDS.
You may also be interested in...
HIV may be effectively treated and managed with available therapies, but there is still great unmet need for a functional cure and better prevention to stop the epidemic.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.